Publications

Journal Publications

PLOS ONE PUBLICATION: TOXICOLOGICAL AND PHARMACOLOGICAL ASSESSMENT OF AGEN1884, A NOVEL HUMAN IGG1 ANTI-CTLA-4 ANTIBODY


CANCER CELL PUBLICATION: SELECTIVE FCGR CO-ENGAGEMENT ON APCS MODULATES THE ACTIVITY OF THERAPEUTIC ANTIBODIES TARGETING T CELL ANTIGENS


PROPHAGETM VACCINE PUBLICATIONS

GLIOMA

Phase 2

Bloch O, Lim M, Sughrue ME, Komotar RJ, Abrahams JM, O’Rourke DM, D’Ambrosio A, Bruce JN, Parsa AT. Autologous heat shock protain peptide vaccination for newly diagnosed Glioblastoma: impact of peripheral PD-L1 expression on response to therapy. Clin Cancer Res. 2017 In Press.

Phase 2 (Protocol C-100-34)

Parsa et al., Neuro Oncol. 2014 Jan;16(2):274-9. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial.

Crane CA, Han SJ, Ahn B, Oehlke J, Kivett V, Fedoroff A, Butowski N, Chang SM, Clarke J, Berger MS, McDermott MW, Prados MD, Parsa AT. Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein. Clin Cancer Res. 2013 Jan 1;19(1):205-14.

Phase 2 (Protocol C-100-37)

Bloch O, Kaur T, Aghi M et al. Progression-Free Survival In A Trial of Immunotherapy For Glioblastoma [abstract]. In: Proceedings of the 81st Annual Meetings of the American Association of Neurological Surgeons; 2013 April 28-May 1; New Orleans, LA: J. Neurosurgery 2013; vol 119. p. A565. Abstract nr 801.

RENAL CELL CARCINOMA (RCC)

Phase 3 survival update (Protocol C-100-27)

Wood C, Srivastava P, Lacombe L, et al. Survival update from a multicenter, randomized, phase III trial of vitespen versus observation as adjuvant therapy for renal cell carcinoma in patients at high risk of recurrence. J Clin Oncol. 27:15s, 2009(suppl; abstr 3009).

Phase 3 (Protocol C-100-12)

Wood C, Srivastava P, Bukowski R, et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet.2008;372(9633):145-154.

Phase 2 (Protocol C-100-07)

Jonasch E, Wood C, Tamboli P, et al. Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings. Br J Cancer. 2008;98:1366-1341.

MELANOMA

Phase 3 (Protocol C-100-21)

Testori A, Richards J, Whitman E, et al. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician’s choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol. 2008;26:955-962.

Phase 2 (Protocol C-100-06)

Belli F, Testori A, Rivoltini L, et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol. 2002;20:4169-4180.

Phase 2 (Protocol C-100-22)

Pilla L, Patuzzo R, Rivoltini L, et al. A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients. Cancer Immunol Immunother. 2006;55:958-968.

Phase 1/2 (Protocol C-100-02)

Eton O, Ross MI, East MJ, et al. Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma. J Trans Med. 2010;8:9.

COLORECTAL CANCER

Phase 2 (Protocol C-100-05)

Mazzaferro V, Coppa J, Carrabba MG, et al. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin Cancer Res. 2003;9:3235-3245.

PANCREATIC CANCER

Phase 1 (Protocol C-100-01)

Maki RG, Livingston PO, Lewis JJ, et al. A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma. Dig Dis Sci. 2007;52:1964-1972.

NON-SMALL CELL LUNG CANCER

Phase 1 (Protocol C-100-26)

Santis G, Senzer NN, Champagne P, Isakov L, Teofilovici F, et al. Phase II feasibility study of autologous vaccine (HSPPC-96) in patients with resectable lung cancer. J Clin Oncol. 2008;26: (May 20 suppl; abstr 7584).

NON-HODGKIN’S LYMPHOMA

Phase 2 (Protocol C-100-09)

Oki Y, McLaughlin P, Fayad LE, et al. Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma. Cancer. 2007;109:77-83.

GASTRIC CANCER

Phase 1 (Protocol C-100-04)

Hertkorn C, Lehr A, Woelfel T, et al. Phase I trial of vaccination with autologous tumor-derived gp96 (Oncophage) in patients after surgery for gastric cancer. J Clin Oncol. 2002 (abstr 117).

OTHER CLINICAL TRIAL PUBLICATIONS

Srivastava PK, Callahan MK, Mauri MM. Treating human cancers with heat shock protein-peptide complexes: the road ahead. Expert Opin Biol Ther. 2009;9:179-86.

Li Z, Qiao Y, Liu B, et al. Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia. Clin Cancer Res. 2005;11:4460-4468.

Pilla L, Squarcina P, Coppa J, et al. Natural killer and NK-like T-cell activation in colorectal carcinoma patients treated with autologous tumor-derived heat shock protein 96. Cancer Res. 2005;65:3942-3949.

Rivoltini L, Castelli C, Carrabba M, et al. Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells. J Immunol. 2003;171:3467-3474.

Castelli C, Ciupitu AM, Rini F, et al. Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells. Cancer Res. 2001;61:222-227.

Janetzki S, Palla D, Rosenhauer V, Lochs H, Lewis JJ, Srivastava PK. Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study. Int J Cancer. 2000;88:232-238


QS-21 STIMULON® ADJUVANT PUBLICATIONS

  • Cunningham AL, Lal H, Kovac M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375(11):1019-1032.
  • Agnandji ST, Lell B, Soulanoudjingar SS, et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med.2011;365(20):1863-75.
  • Garçon N, Van Mechelen M. Recent clinical experience with vaccines using MPL- and QS-21- containing adjuvant systems. Expert Rev Vaccines. 2011;10(4):471-86.
  • Aide P, Dobaño C, Sacarlal J, et al. Four year immunogenicity of the RTS,S/AS02(A) malaria vaccine in Mozambican children during a phase IIb trial. Vaccine. 2011;29(35):6059-67.
  • Bejon P, Cook J, Bergmann-Leitner E, et al. Effect of the pre-erythrocytic candidate malaria vaccine RTS,S/AS01E on blood stage immunity in young children. J Infect Dis. 2011;204(1):9-18.
  • Asante KP, Abdulla S, Agnandji S, et al. Safety and efficacy of the RTS,S/AS01(E) candidate malaria vaccine given with expanded-programme-on immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. Lancet Infect Dis. 2011 ;11(10):741-9.
  • Wald A, Koelle DM, Fife K, et al. Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive persons. Vaccine. 2011 Sep 21.
  • Mo A, Musselli C, Chen H, et al. A heat shock protein based polyvalent vaccine targeting HSV-2: CD4(+) and CD8(+) cellular immunity and protective efficacy. Vaccine. 2011 Jul 19.
  • Surquin M, Tielemans CL, Kulcsar I, et al.  Rapid, enhanced, and persistent protection of patients with renal insufficiency by AS02(V)-adjuvanted hepatitis B vaccine. Kidney Int. 2010;77:247-255.
  • Abdulla S, Oberholzer R, Juma O, et al. Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. N Engl J Med.2008;359:2533-2544.
  • Bejon P, Lusingu J, Olotu A, et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med.2008;359:2521-2532.
  • Brichard VG, Lejeune D. Cancer immunotherapy targeting tumour-specific antigens: towards a new therapy for minimal residual disease. Expert Opin Biol Ther. 2008;8:951-968.
  • Vandepapeliere P, Horsmans Y, Moris P, et al. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine. 2008;26:1375-1386.
  • Warfield KL, Olinger G, Deal EM, et al. Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection. J Immunol. 2005;175:1184-1191.
  • Schaed SG, Klimek BM, Panageas KS, et al. T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund’s adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants. Clin Cancer Res. 2002;8:967-972.
  • Boyaka PN, Marinaro M, Jackson RJ, et al. Oral QS-21 requires early IL-4 help for induction of mucosal and systemic immunity. J Immunol.2001;166:2283-2290.
  • Evans TG, McElrath MJ, Matthews T, et al. QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. Vaccine. 2001;19:2080-2091.
  • Waite DC, Jacobson EW, Ennis FA, et al. Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21. Vaccine. 2001;19:3957-3967.
  • Nardin EH, Oliveira GA, Calvo-Calle JM, et al. Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccines of defined HLA genotypes. J Infect Dis. 2000;182:1486-1496.
  • Kim SK, Ragupathi G, Musselli C, Choi SJ, Park YS, Livingston PO. Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines. Vaccine. 1999;18:597-603.
  • Sasaki S, Sumino K, Hamajima K, et al. Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes. J Virol. 1998;72:4931-4939.
  • Stoute JA, Slaoui M, Heppner DG, et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med. 1997;336:86-91.
  • Jacobsen NE, Fairbrother WJ, Kensil CR, Lim A, Wheeler DA, Powell MF. Structure of the saponin adjuvant QS-21 and its base-catalyzed isomerization product by 1H and natural abundance 13C NMR spectroscopy. Carbohydr Res. 1996;280:1-14.
  • Helling F, Zhang S, Shang A, et al. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res. 1995;55:2783-2788.
  • Kensil CR. Saponins as vaccine adjuvants. Crit Rev Ther Drug Carrier Syst. 1996;13:1-55.
  • Newman MJ, Wu JY, Gardner BH, et al. Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses. J Immunol. 1992;148:2357-2362.
  • Kensil CR, Patel U, Lennick M, Marciani D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J Immunol. 1991;146:431-437.